In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on RxSight (RXST – Research Report), with a price target of $61.00. The company’s shares closed yesterday at $56.39.
Lichtman covers the Healthcare sector, focusing on stocks such as RxSight, MannKind, and Merit Medical Systems. According to TipRanks, Lichtman has an average return of 12.2% and a 52.66% success rate on recommended stocks.
Currently, the analyst consensus on RxSight is a Strong Buy with an average price target of $53.13, representing a -5.78% downside. In a report released today, Needham also reiterated a Buy rating on the stock with a $64.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $58.04 and a one-year low of $13.00. Currently, RxSight has an average volume of 519K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RXST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RxSight (RXST) Company Description:
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Read More on RXST:
- RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
- RxSight price target raised to $61 from $43 at BTIG
- RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- RxSight price target raised to $54 from $45 at Stifel
- RxSight price target raised to $41 from $35 at Needham
